PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Click here for the link to this article.
Read moreDr. Ben Sessa discusses his latest research here.
The Department of Veterans Affairs issued a request for applications (RFA) for proposals from its network of VA researchers (in collaboration with academic institutions) to study the use of certain psychedelic compounds in treating posttraumatic stress disorder (PTSD) and depression.
Read moreNew research has found that stressful or unsafe environments, negative expectations and a lack of social support during and after the psychedelic experience were all associated with negative outcomes when taking psychedelics.
Read moreThis research article looks at some preliminary clinical findings that suggest potential efficacy of psychedelics for chronic pain, and the need for further research.
Read moreThis podcast discusses how psychedelics reopen critical periods of learning, and how the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them.
Read moreThe most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization.
For approximately one-third of the participants, problems persisted for over a year, and for a sixth, they endured for more than three years.
It was found that a shorter duration of difficulties was predicted by knowledge of dose, drug type and lower levels of difficulty reported during the psychoactive experience, while a narrower range of difficulties was predicted by taking the drug in a guided setting.
Read moreA new study suggests that dosage, age, and neuroticism may predict the intensity of a psychedelic experience, whether mystical (positive) or challenging.
Read more